According to an analysis by Bloomberg, Novartis is interested in finding a competitive Alzheimer's drug program. But it's hard to determine from the story if the pharma giant--always reluctant to deta…
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!Novartis AG (NOVN) plans to ramp up its research in Alzheimers disease, a potential $20 billion market lackin…
Atlas Venture, an early-stage venture capital firm that invests in technology and life sciences companies, has entered into Corporate Strategic Partnership (CSP) agreements with both Amgen, through it…
The FDA has approved Novartis drug Ilaris canakinumab for the treatment of active systemic juvenile idiopathic arthritis SJIA in patients aged two years and older. Ilaris is the first interleukin1 bet…
